Glysantis Inc. Selected as a Finalist in RESI Toronto Innovation Challenge at Toronto Health Innovation Week 2018.

Guelph, April 4, 2018 – Glysantis Inc. today announced that it has been selected as a finalist in the RESI at MaRS Toronto Innovation Challenge. Glysantis Inc. will be one of 30 early-stage biotech, med-tech and digital health startups to showcase a poster vying for “RESI bucks” given to attendees to “invest” in the most promising startups.

CEO Dr. Phil Whiting and Ricky Ghoshal, Sr. Business Development Associate, will attend the RESI conference at MaRS on Tuesday, April 10, 2018 with a focus on introducing early stage biotech investors to Glysantis Inc.

Glysantis will be showcasing its proprietary nanotechnology platform based on NanoDendrix™ – a unique, monodisperse nanomaterial derived from Ontario sweet corn. The company will highlight selected applications of NanoDendrix™ nanoparticles in enhancing yields of viruses produced in cell culture, drug delivery and anti-infectives.

“RESI is a great opportunity to showcase Glysantis and introduce the NanoDendrix™ platform to early stage investors”, said Phil Whiting. “Glysantis is already scheduled to engage in one-on-one partnering meetings with a number of institutional, venture capital and corporate investors”.

The Redefining Early Stage Investments (RESI) Conference, produced by Life Science Nation, is an ongoing conference series that provides an international venue for early stage life science companies across Biotech, Medtech, Diagnostics and Healthcare IT and to source investors from around the globe, create relationships, and eventually, secure funding. The RESI conference takes place in San Francisco in January, in Toronto in April, in Boston in June & September, and in New York City in November. Fundraising companies have a venue to meet early stage investors that are a fit for their sector and stage every three months.

Glysantis Inc., a wholly-owned subsidiary of Mirexus Biotechnologies Inc. (MBI), is a biotechnology company active in pre-clinical research & development of an innovative nanoparticle technology platform, NanoDendrix™, based on monodisperse phytoglycogen extracted from Ontario sweet corn. These naturally assembled nanoparticles are safe, non-toxic, fully biodegradable and can be chemically modified. Glysantis’ R&D efforts are developing applications in diverse areas such as vaccine biomanufacturing, anti-infectives, oral health, immune-modulation and targeted drug delivery. Our scalable technology provides safe nanoparticles for a wide range of applications.

Company contact details:

Ricky Ghoshal
Sr. Business Development Associate
Phone: +1 519 835 2243
E-mail: rghoshal@glysantis.com
www.glysantis.com